Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies

Stock Information for Tiziana Life Sciences plc

Loading

Please wait while we load your information from QuoteMedia.